ANI Pharmaceuticals ANIP Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Revenues by Business | ||||||
| Generics and Other | $405.61M+16.5% | $399.43M+24.8% | $379.63M+23.0% | $363.65M+21.9% | $348.26M+19.3% | |
| Rare Disease and Brands | $518.09M+59.0% | $483.93M+64.4% | $447.25M+88.8% | $383.75M+74.0% | $325.81M+54.6% | |
| Other (expense)income , net by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | ||||||
| Generics and Other | $146.76M+8.2% | $154.99M+33.6% | $146.18M+23.8% | $143.72M+28.3% | $135.58M+25.0% | |
| Rare Disease and Brands | $156.36M+122% | $141.24M+94.9% | $120.88M+82.8% | $84.65M+2.0% | $70.5M-21.6% | |
| Operating Income (Loss) by Business | ||||||
| Generics and Other | $146.76M+8.2% | $154.99M+33.6% | $146.18M+23.8% | $143.72M+28.3% | $135.58M+25.0% | |
| Rare Disease and Brands | $156.36M+122% | $141.24M+94.9% | $120.88M+82.8% | $84.65M+2.0% | $70.5M-21.6% | |
| Net Interest Expense by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Cost of sales (excluding depreciation and amortization) by Business | ||||||
| Generics and Other | $215.05M+20.8% | $201.96M+19.9% | $190.44M+19.3% | $179.29M+15.5% | $178.07M+17.7% | |
| Rare Disease and Brands | $146.81M+52.9% | $139.36M+70.3% | $130.88M+135% | $111.72M+163% | $96.02M+183% | |
| Selling, General and Administrative Expense by Business | ||||||
| Generics and Other | $5.79M+4.9% | $5.68M+10.8% | $5.59M+28.4% | $5.56M+55.4% | $5.52M+93.8% | |
| Rare Disease and Brands | $201.24M+40.0% | $188.49M+49.6% | $176.86M+68.3% | $168.58M+92.1% | $143.74M+80.2% | |
| Unrealized gain (loss) on investment in equity securities by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Research and Development expense by Business | ||||||
| Generics and Other | $38.02M+30.7% | $36.82M+20.6% | $37.42M+40.6% | $35.08M+27.3% | $29.09M-0.3% | |
| Rare Disease and Brands | $13.68M-12.0% | $14.85M+5.6% | $18.63M+88.4% | $18.8M+154% | $15.55M+120% | |
| D&A by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Contingent consideration fair value adjustment by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Net Revenues by Product | ||||||
| Brands | $48.51M-24.4% | $61.31M-5.3% | $68.84M+3.9% | $67.36M-14.1% | $64.19M-28.5% | |
| Cortrophin Gel | $370.05M+72.9% | $347.78M+75.6% | $295.75M+63.9% | $246.45M+56.4% | $214M— | |
| Generic pharmaceutical products | $390.83M+18.6% | $384.11M+27.6% | $361.95M+23.0% | $345.8M+20.7% | $329.47M+19.4% | |
| ILUVIEN and YUTIQ | $78.01M+63.8% | $74.87M+138% | $82.67M+2,036% | $69.94M— | $47.62M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ANI Pharmaceuticals break its business down?
- ANI Pharmaceuticals (ANIP) reports net revenues by business across 2 parts — Generics and Other and Rare Disease and Brands. Each is extracted from the segment footnotes and tracked over time.
- Where does ANI Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ANI Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
